Profitability
Weight: 20%
F
0
- 5yr Avg ROIC -28.8%
- Operating Margin Trend -134.91 pp/yr
EYPT
EyePoint Pharmaceuticals, Inc.
AlphaQuality composite grade, weighted for stable earnings power businesses.
⚠ 5 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a stable earnings power business.
Grade overrides the 17.3 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
0
- 5yr Avg ROE -38.8%
- 5yr Share-Count CAGR 26.3%
Growth Quality
Weight: 15%
F
24
- 5yr Revenue CAGR -4.0%
- 5yr EPS CAGR 0.0%
- Revenue-Growth Years (5) 3/5
Cash Generation
Weight: 15%
F
0
- 5yr FCF Margin -275.7%
- 5yr FCF/NI Conversion 0.00x
Balance Sheet
Weight: 20%
F
21
- Net Debt / EBITDA 10.00x
- Interest Coverage (EBIT/Int) -7376.79x
- Altman Z-Score 3.19
Stability
Weight: 15%
B-
63
- EPS Volatility (σ/μ) 0.00
- Piotroski F-Score 1
- Negative-Revenue Years (5) 2/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.Not enough curated-guru data to call a flow.
- Wood new